Maritupirdine

Maritupirdine (developmental code name AVN-101), a close structural analogue of latrepirdine, is a selective 5-HT₆ receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders.^[1][2][3] As of November 2013, it was in phase II clinical trials for these indications.^{[2][3][4][needs update]}

Maritupirdine

Identifiers
IUPAC name 2,8-Dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
CAS Number	1025725-91-0 Y 1061354-48-0 (hydrochloride)
ChemSpider	24643855
UNII	6MHR5IV28S
ChEMBL	ChEMBL592752
CompTox Dashboard (EPA)	DTXSID901032403
Chemical and physical data
Formula	C21H24N2
Molar mass	304.437 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cc1ccc2c(c1)c3c(n2CCc4ccccc4)CCN(C3)C
InChI InChI=1S/C21H24N2/c1-16-8-9-20-18(14-16)19-15-22(2)12-11-21(19)23(20)13-10-17-6-4-3-5-7-17/h3-9,14H,10-13,15H2,1-2H3 Key:IBUHDDLETPJVGP-UHFFFAOYSA-N

It was approved in Russia on May 31, 2023 under the brand name Aviandr for the treatment of generalized anxiety disorder, mild-to-moderate anxiety conditions (stress reactions and adjustment disorders) and anxiety after COVID-19.^[5]

See also

• List of investigational anxiolytics
• AVN-211